Review




Structured Review

Absolute Biotech Inc rabbit anti-human fap polyclonal antibody
Rabbit Anti Human Fap Polyclonal Antibody, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti-human fap polyclonal antibody/product/Absolute Biotech Inc
Average 90 stars, based on 1 article reviews
rabbit anti-human fap polyclonal antibody - by Bioz Stars, 2026-06
90/100 stars

Images



Similar Products

94
Bioss rabbit polyclonal antibody against human fap
Rabbit Polyclonal Antibody Against Human Fap, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit polyclonal antibody against human fap/product/Bioss
Average 94 stars, based on 1 article reviews
rabbit polyclonal antibody against human fap - by Bioz Stars, 2026-06
94/100 stars
  Buy from Supplier

91
Bio-Rad rabbit polyclonal anti human fapα
Changes in CXCL12, CXCR4, and <t>FAPα</t> expression after neoadjuvant chemoradiotherapy (nCRT) in LARC patients. (A) and (B) Boxplot of CXCL12, CXCR4, and FAPα expression in tumor and irradiated tumor tissues (using dataset GSE15781 and GSE94104). (C) Boxplot of CXCL12, CXCR4, and FAPα expression in normal and irradiated normal adjacent tissues (using dataset GSE15781). * p < 0.05, ** p < 0.01, ns: not significant. Mann-Whitney U test (A, B, and C).
Rabbit Polyclonal Anti Human Fapα, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit polyclonal anti human fapα/product/Bio-Rad
Average 91 stars, based on 1 article reviews
rabbit polyclonal anti human fapα - by Bioz Stars, 2026-06
91/100 stars
  Buy from Supplier

90
Absolute Biotech Inc rabbit anti-human fap polyclonal antibody
Changes in CXCL12, CXCR4, and <t>FAPα</t> expression after neoadjuvant chemoradiotherapy (nCRT) in LARC patients. (A) and (B) Boxplot of CXCL12, CXCR4, and FAPα expression in tumor and irradiated tumor tissues (using dataset GSE15781 and GSE94104). (C) Boxplot of CXCL12, CXCR4, and FAPα expression in normal and irradiated normal adjacent tissues (using dataset GSE15781). * p < 0.05, ** p < 0.01, ns: not significant. Mann-Whitney U test (A, B, and C).
Rabbit Anti Human Fap Polyclonal Antibody, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti-human fap polyclonal antibody/product/Absolute Biotech Inc
Average 90 stars, based on 1 article reviews
rabbit anti-human fap polyclonal antibody - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Santa Cruz Biotechnology rabbit anti-human fap-1 polyclone antibody
Changes in CXCL12, CXCR4, and <t>FAPα</t> expression after neoadjuvant chemoradiotherapy (nCRT) in LARC patients. (A) and (B) Boxplot of CXCL12, CXCR4, and FAPα expression in tumor and irradiated tumor tissues (using dataset GSE15781 and GSE94104). (C) Boxplot of CXCL12, CXCR4, and FAPα expression in normal and irradiated normal adjacent tissues (using dataset GSE15781). * p < 0.05, ** p < 0.01, ns: not significant. Mann-Whitney U test (A, B, and C).
Rabbit Anti Human Fap 1 Polyclone Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti-human fap-1 polyclone antibody/product/Santa Cruz Biotechnology
Average 90 stars, based on 1 article reviews
rabbit anti-human fap-1 polyclone antibody - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
Santa Cruz Biotechnology rabbit anti-human fap-1 polyclone antibody (santa cruz)
Changes in CXCL12, CXCR4, and <t>FAPα</t> expression after neoadjuvant chemoradiotherapy (nCRT) in LARC patients. (A) and (B) Boxplot of CXCL12, CXCR4, and FAPα expression in tumor and irradiated tumor tissues (using dataset GSE15781 and GSE94104). (C) Boxplot of CXCL12, CXCR4, and FAPα expression in normal and irradiated normal adjacent tissues (using dataset GSE15781). * p < 0.05, ** p < 0.01, ns: not significant. Mann-Whitney U test (A, B, and C).
Rabbit Anti Human Fap 1 Polyclone Antibody (Santa Cruz), supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti-human fap-1 polyclone antibody (santa cruz)/product/Santa Cruz Biotechnology
Average 90 stars, based on 1 article reviews
rabbit anti-human fap-1 polyclone antibody (santa cruz) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

Image Search Results


Changes in CXCL12, CXCR4, and FAPα expression after neoadjuvant chemoradiotherapy (nCRT) in LARC patients. (A) and (B) Boxplot of CXCL12, CXCR4, and FAPα expression in tumor and irradiated tumor tissues (using dataset GSE15781 and GSE94104). (C) Boxplot of CXCL12, CXCR4, and FAPα expression in normal and irradiated normal adjacent tissues (using dataset GSE15781). * p < 0.05, ** p < 0.01, ns: not significant. Mann-Whitney U test (A, B, and C).

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Changes in CXCL12, CXCR4, and FAPα expression after neoadjuvant chemoradiotherapy (nCRT) in LARC patients. (A) and (B) Boxplot of CXCL12, CXCR4, and FAPα expression in tumor and irradiated tumor tissues (using dataset GSE15781 and GSE94104). (C) Boxplot of CXCL12, CXCR4, and FAPα expression in normal and irradiated normal adjacent tissues (using dataset GSE15781). * p < 0.05, ** p < 0.01, ns: not significant. Mann-Whitney U test (A, B, and C).

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Expressing, Irradiation, MANN-WHITNEY

Correlation of CXC chemokine ligand 12 (CXCL12), CXC chemokine type 4 (CXCR4), and fibroblast activation protein-α  (FAPα)  expression with clinicopathological factors in 121 patients with locally advanced rectal cancer.

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Correlation of CXC chemokine ligand 12 (CXCL12), CXC chemokine type 4 (CXCR4), and fibroblast activation protein-α (FAPα) expression with clinicopathological factors in 121 patients with locally advanced rectal cancer.

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Activation Assay, Expressing

Images showing immunohistochemical staining of CXCL12, CXCR4, and FAPα in the case of each pathways in locally advanced rectal cancer (LARC) after neoadjuvant chemoradiotherapy (LARC-nCRT) (A,C,E) and LARC with no nCRT (LARC-no nCRT) (B,D,E). In the case of LARC-nCRT, the expression of CXCL12, CXCR4, and FAPα is higher than in the case of LARC-no nCRT (original magnification 400× ; scale bar= 50 µm).

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Images showing immunohistochemical staining of CXCL12, CXCR4, and FAPα in the case of each pathways in locally advanced rectal cancer (LARC) after neoadjuvant chemoradiotherapy (LARC-nCRT) (A,C,E) and LARC with no nCRT (LARC-no nCRT) (B,D,E). In the case of LARC-nCRT, the expression of CXCL12, CXCR4, and FAPα is higher than in the case of LARC-no nCRT (original magnification 400× ; scale bar= 50 µm).

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Immunohistochemical staining, Staining, Expressing

Comparison of the levels of CXCL12, CXCR4, and FAPα by immunohistochemical staining among pathways in locally advanced rectal cancer (LARC) after neoadjuvant chemoradiotherapy (nCRT) (LARC-nCRT) (n = 61), LARC untreated with nCRT (LARC-no nCRT) (n = 60) and high-grade dysplasia of colorectal adenoma (HD) (n = 16). The levels of the three proteins were higher in LARC-nCRT than in LARC-no nCRT or HD (p < 0.001 for each). (A) CXCL12 positivity: 62.3%, 38/61 LARC-nCRT cases; 5.0%, 3/60 LARC-no nCRT cases; and 0.0%, 0/16 HD cases. (B) CXCR4 positivity: 47.5%, 29/61 LARC-nCRT cases; 0.0%, 0/60 LARC-no nCRT cases; and 0.0%, 0/16 HD cases. (C) FAPα positivity: 62.3%, 38/61 LARC-nCRT cases; 25.0%, 15/60 LARC-no nCRT cases; and 0.0%, 0/16 HD cases.

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Comparison of the levels of CXCL12, CXCR4, and FAPα by immunohistochemical staining among pathways in locally advanced rectal cancer (LARC) after neoadjuvant chemoradiotherapy (nCRT) (LARC-nCRT) (n = 61), LARC untreated with nCRT (LARC-no nCRT) (n = 60) and high-grade dysplasia of colorectal adenoma (HD) (n = 16). The levels of the three proteins were higher in LARC-nCRT than in LARC-no nCRT or HD (p < 0.001 for each). (A) CXCL12 positivity: 62.3%, 38/61 LARC-nCRT cases; 5.0%, 3/60 LARC-no nCRT cases; and 0.0%, 0/16 HD cases. (B) CXCR4 positivity: 47.5%, 29/61 LARC-nCRT cases; 0.0%, 0/60 LARC-no nCRT cases; and 0.0%, 0/16 HD cases. (C) FAPα positivity: 62.3%, 38/61 LARC-nCRT cases; 25.0%, 15/60 LARC-no nCRT cases; and 0.0%, 0/16 HD cases.

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Comparison, Immunohistochemical staining, Staining

Univariate analysis of overall survival and freedom from recurrence in 61 cases of locally advanced rectal cancer with neoadjuvant chemoradiotherapy.

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Univariate analysis of overall survival and freedom from recurrence in 61 cases of locally advanced rectal cancer with neoadjuvant chemoradiotherapy.

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Expressing

Multivariate analysis of overall survival and Freedom from recurrence in 61 cases of locally advanced rectal cancer with neoadjuvant chemoradiotherapy.

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Multivariate analysis of overall survival and Freedom from recurrence in 61 cases of locally advanced rectal cancer with neoadjuvant chemoradiotherapy.

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Expressing

Kaplan-Meier survival curves-estermates of freedom from recurrence of colorectal cancer in 61 cases of locally advanced rectal cancer (LARC) with neoadjuvant chemoradiotherapy according to plasma membrane expressions of CXCL12, CXCR4 and FAPα in tumor cells. (A) CXCL12, (B) CXCR4, and (C) FAPα.

Journal: Journal of Cancer

Article Title: Elevated CXCL12 in the plasma membrane of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a potential prognostic marker

doi: 10.7150/jca.64082

Figure Lengend Snippet: Kaplan-Meier survival curves-estermates of freedom from recurrence of colorectal cancer in 61 cases of locally advanced rectal cancer (LARC) with neoadjuvant chemoradiotherapy according to plasma membrane expressions of CXCL12, CXCR4 and FAPα in tumor cells. (A) CXCL12, (B) CXCR4, and (C) FAPα.

Article Snippet: The tissue sections were incubated at 37 °C for 30 min with the mouse monoclonal anti-human CXCL12 (1:300, catalog #MA5-23759, Invitrogen, Rockford, IL, USA), the rabbit monoclonal anti-human CXCR4 (1:100, catalog #ab124824, Abcam, Cambridge, UK), and the rabbit polyclonal anti-human FAPα (1:20, catalog #AHP1322, BIO-RAD, Hercules, CA, USA).

Techniques: Clinical Proteomics, Membrane